Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision tag on the page updated from v3.6.3 to v3.6.4, indicating a new release of the page's content-management or rendering logic.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision: v3.6.3 replaces v3.6.1 on the page, signaling a software update to the site. The study content and data remain unchanged as a result of this update.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page’s revision label has been updated from Revision: v3.6.0 to Revision: v3.6.1. This is a minor metadata update that does not alter the study content or data presented.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page shows a new Revision: v3.5.5 label, replacing the previous Revision: v3.5.4. This indicates an update to the page's revision history rather than a change to study content.SummaryDifference0.0%

- Check76 days agoChange DetectedA new publication reference has been added to the Publications section, citing a 2026 Ther Adv Hematol article on ruxolitinib in GVHD. This addition expands the related literature linked to the REACH3 study page without modifying study details or eligibility.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page's revision has been updated to v3.5.4, signaling a small maintenance or metadata update rather than a change to the study data.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.